relapsing polychondritis: Relapsing polychondritis (RP) is a rare, clinically heterogeneous, multisystemic inflammatory disease characterized by inflammation of the cartilage and proteoglycan rich structures leading to cartilage damage with joint, ocular and cardiovascular involvement.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
88 |
4. Check minimum number of eventsNone |
88 |
5. Include endpointsNone |
88 |
6. Filter based on genotype QC (FinnGen only) |
84 |
Control definitions (FinnGen only)
- Control exclude
- M13_OTHERBONE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M94
- Name in latin
- Polychondritis recidiva
Similar endpoints
↥List of similar endpoints to
Relapsing polychondritis
based on the number of shared cases.
Similar with more cases:
- Chondropathies
- Other disorders of bone
- Osteopathies and chondropathies
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 349 | 227 | 121 |
| Only index persons | 333 | 217 | 116 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 52.03 | 50.64 | 54.42 |
| Only index persons | 51.38 | 50.03 | 53.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 84 | 61 | 23 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 51.46 | 49.84 | 55.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 88
- Matched controls
- 880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M94.1
ICD-10 Finland
Relapsing polychondritis
+∞
126.7
88
*
L04AX03
ATC
methotrexate; systemic
22.3
50.6
53
56
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
15.3
38.2
48
64
H02AB06
ATC
prednisolone; systemic
8.2
16.3
72
311
H61.0
ICD-10 Finland
Perichondritis of external ear
+∞
12.8
12
*
P01BA02
ATC
hydroxychloroquine; oral
6.4
11.8
23
46
L04AX01
ATC
azathioprine; systemic
18.8
11.4
17
11
A46
ICD-10 Finland
Erysipelas
5.6
11.2
26
61
L01BA01
ATC
methotrexate; systemic
17.2
11.0
17
12
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
6.5
10.2
19
36
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.4
10.0
60
289
H02AB07
ATC
prednisone; oral
5.3
9.9
24
58
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.1
9.6
42
161
R03BA05
ATC
fluticasone; inhalant
4.0
7.8
29
97
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.8
7.7
31
110
H62.0*A46
ICD-10 Finland
Otitis externa in erysipelas
33.0
7.3
9
*
J01DB01
ATC
cefalexin; oral
10.0
7.2
85
651
H60.1
ICD-10 Finland
Cellulitis of external ear
24.8
6.8
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
6.4
45
221
J01FA06
ATC
roxithromycin; oral
3.1
6.4
51
269
M94.9
ICD-10 Finland
Disorder of cartilage, unspecified
+∞
6.3
6
*
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Proper column names.
- Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV not working.
- No filters and sorters.
- Limited amount of endpoints with TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
Relapsing polychondritis
M94.1 (45572688)
M94.1 (45572688)
prednisolone
A07EA01 (21600653)
A07EA01 (21600653)
methotrexate
L01BA01 (21601423)
L01BA01 (21601423)
prednisolone; oral, parenteral
H02AB06 (21602734)
H02AB06 (21602734)
methotrexate; oral, parenteral
L04AX03 (21603929)
L04AX03 (21603929)
Otolaryngology
4 (38004449)
4 (38004449)
Internal Medicine
11 (38004456)
11 (38004456)
Differential panel, method unspecified - Blood
69738-3 (42870588)
69738-3 (42870588)
Pharmacy visit
OMOP4822462 (581458)
OMOP4822462 (581458)
Monocytes [#/volume] in Blood
26484-6 (3001604)
26484-6 (3001604)
Basophils [#/volume] in Blood
26444-0 (3006315)
26444-0 (3006315)
Rheumatology
66 (38004491)
66 (38004491)
Eosinophils [#/volume] in Blood
26449-9 (3013115)
26449-9 (3013115)
Lymphocytes [#/volume] in Blood
26474-7 (3019198)
26474-7 (3019198)
Monocytes/Leukocytes in Blood
26485-3 (3019069)
26485-3 (3019069)
Neutrophils/Leukocytes in Blood
26511-6 (3018010)
26511-6 (3018010)
Eosinophils/Leukocytes in Blood
26450-7 (3006504)
26450-7 (3006504)
Basophils/Leukocytes in Blood
30180-4 (3022096)
30180-4 (3022096)
Lymphocytes/Leukocytes in Blood
26478-8 (3002030)
26478-8 (3002030)
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 (3013707)
4537-7 (3013707)
Neutrophils [#/volume] in Blood by Automated count
751-8 (3013650)
751-8 (3013650)
Emergency Room Visit
ER (9203)
ER (9203)
Outpatient Visit
OP (9202)
OP (9202)
Supplier / Service Provider
OMOP5117446 (33004)
OMOP5117446 (33004)
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (3020460)
1988-5 (3020460)
Case Management Agency
251B00000X (38004193)
251B00000X (38004193)
Nuclear Ab [Titer] in Serum
29953-7 (3037522)
29953-7 (3037522)
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 (3001668)
19875-4 (3001668)
FEV1/FVC
19926-5 (3011505)
19926-5 (3011505)
Forced vital capacity [Volume] Respiratory system
19870-5 (3020158)
19870-5 (3020158)
FEV1 --post bronchodilation
20155-8 (3023550)
20155-8 (3023550)
FEV1
20150-9 (3024653)
20150-9 (3024653)
FEV1/FVC --post bronchodilation
69970-2 (42868459)
69970-2 (42868459)
FVC percent change Respiratory system
69982-7 (42868471)
69982-7 (42868471)
FEV1 percent change
69983-5 (42868472)
69983-5 (42868472)
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
24
42
7.48
14.08
2.4
1.6
14.06
3.69
iu/ml
—
5
7
73
429
5.12
8.73
5.5
3.9
0.00
0.00
estimate
-0.00
16
100
73
437
4.93
8.32
5.6
3.8
75.44
0.00
estimate
0.48
18
100
73
439
4.89
8.21
5.5
3.9
0.00
0.00
estimate
-0.00
16
95
42
191
3.29
6.97
1.6
1.3
11.09
36.92
iu/ml
1.77
13
54
10
10
11.09
5.69
1.2
1.0
—
—
—
0
0
37
176
2.90
5.43
1.4
1.4
1.06
9.41
u/ml
1.89
16
69
11
15
8.20
5.33
1.2
1.2
—
—
—
0
0
11
16
7.68
5.13
1.2
1.3
—
—
—
0
0
41
225
2.54
4.36
3.0
2.6
0.12
0.42
e6/l
1.83
34
164
9
13
7.57
4.28
1.2
1.2
—
—
—
0
0
9
13
7.57
4.28
1.2
1.2
—
—
—
0
0
9
13
7.57
4.28
1.2
1.2
—
—
—
0
0
9
13
7.57
4.28
1.2
1.2
—
—
—
0
0
11
22
5.55
4.16
1.5
1.4
—
—
—
0
0
24
103
2.83
4.12
2.1
1.7
—
—
—
0
0
9
16
6.13
3.77
1.2
1.2
—
—
—
0
0
34
186
2.35
3.50
2.6
1.8
0.50
1.53
mg/l
1.84
29
154
21
92
2.68
3.43
5.7
7.6
105.95
103.61
mmol/l
1.65
21
92
17
71
2.73
3.02
2.4
1.6
—
—
—
0
0
17
71
2.73
3.02
2.4
1.6
—
—
—
0
0
6
9
7.05
2.91
3.5
3.4
—
—
—
0
0
12
41
3.23
2.75
7.8
11.0
23.65
24.45
mmol/l
0.49
12
41
50
345
2.04
2.70
5.6
3.7
0.00
0.00
estimate
-0.00
12
86
44
291
2.02
2.66
3.0
3.2
30.77
31.22
u/l
0.04
44
272
39
248
2.03
2.62
6.9
3.9
0.00
0.00
estimate
-0.00
17
94
6
12
5.28
2.44
1.0
1.3
—
—
—
0
0
24
131
2.14
2.38
2.6
2.4
0.77
0.80
e6/l
0.04
11
73
12
48
2.74
2.30
6.8
8.3
24.00
24.86
mmol/l
0.37
12
48
21
112
2.15
2.20
2.6
2.7
0.81
3.63
e6/l
—
8
55
9
31
3.11
2.14
2.2
1.6
—
—
—
0
0
34
219
1.90
2.12
1.5
1.3
3.53
1.51
u/ml
0.27
12
61
5
10
5.22
2.10
1.2
1.6
—
—
—
0
0
5
10
5.22
2.10
1.2
1.6
—
—
—
0
0
10
38
2.84
2.08
1.8
2.4
0.58
0.66
%
—
10
38
39
266
1.84
2.02
5.5
3.2
0.00
0.01
estimate
0.49
13
83
34
222
1.87
2.02
3.0
2.9
590.66
1008.83
ng/l
0.50
28
182
6
16
3.94
1.97
1.2
1.5
—
—
—
0
0
5
11
4.75
1.97
1.2
1.2
—
—
—
0
0
13
59
2.41
1.95
7.5
8.1
0.95
1.23
mmol/l
0.66
13
59
16
80
2.22
1.95
2.6
4.3
223.69
247.53
u/l
0.66
16
80
14
66
2.33
1.94
1.7
3.2
0.06
0.10
e6/l
0.28
14
61
7
22
3.36
1.92
1.6
2.5
—
—
—
0
0
8
28
3.04
1.91
1.0
1.2
1.59
1.69
g/l
—
8
28
5
12
4.35
1.85
1.0
1.6
—
—
—
0
0
8
29
2.93
1.84
1.0
1.2
0.79
0.81
g/l
—
8
29
20
113
2.00
1.79
2.6
2.2
21.79
24.05
%
0.29
20
105
10
40
2.69
1.73
1.8
2.5
1.00
1.32
%
—
10
40
26
165
1.82
1.65
1.9
1.6
—
—
—
0
0
22
134
1.86
1.58
3.2
2.2
11.65
14.16
umol/l
0.85
22
122
8
33
2.56
1.58
1.3
1.5
—
—
—
0
0
13
66
2.14
1.52
1.2
1.2
42.03
141.83
u/ml
—
7
21
5
16
3.25
1.46
1.2
1.6
—
—
—
0
0
76
669
2.00
1.41
36.1
17.8
13.99
13.56
%
1.97
76
662
49
384
1.62
1.40
4.8
3.2
108.49
103.27
ug/l
0.08
49
364
6
23
2.72
1.39
1.3
1.8
—
—
—
0
0
42
319
1.61
1.35
2.2
2.0
99.89
95.24
pmol/l
0.23
26
169
8
35
2.41
1.31
2.8
2.1
25.10
24.59
mmol/l
—
8
35
5
18
2.88
1.30
1.2
1.5
—
—
—
0
0
8
36
2.34
1.28
1.9
1.6
—
—
—
0
0
6
25
2.50
1.26
1.3
2.0
—
—
—
0
0
27
188
1.63
1.21
3.4
3.9
1.02
1.02
kg/l
0.32
17
118
21
137
1.70
1.20
4.5
3.2
169.91
357.20
ng/l
0.34
11
95
45
357
1.53
1.15
2.2
2.8
—
—
estimate
—
0
0
9
48
1.97
1.04
1.4
1.5
—
—
—
0
0
25
178
1.57
1.01
1.9
2.3
—
—
—
0
0
5
97
0.49
0.84
1.6
4.9
39.20
31.73
%
—
5
67
54
464
1.42
0.82
4.4
4.8
6.13
6.52
mmol/l
1.14
54
436
36
290
1.41
0.78
5.0
3.7
15.60
42.58
ng/l
1.24
23
190
5
27
1.90
0.69
1.4
1.1
—
3.84
—
0
5
5
27
1.90
0.69
1.6
1.3
—
—
—
0
0
7
44
1.64
0.67
1.9
1.2
—
—
—
0
0
8
54
1.53
0.59
1.0
1.1
—
—
—
0
0
59
533
1.32
0.55
3.8
3.3
—
—
—
0
0
20
253
0.73
0.55
3.8
4.0
2.44
8.88
mg/mmol
1.69
14
155
13
96
1.42
0.44
3.5
2.2
324.77
360.16
nmol/l
0.35
13
90
13
98
1.38
0.40
3.1
4.8
0.99
1.02
mmol/l
0.13
13
91
10
74
1.40
0.34
2.1
1.3
—
—
—
0
0
13
103
1.31
0.30
2.2
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
11
0.00
0.21
0.0
5.7
—
106.97
—
0
11
10
81
1.26
0.20
4.0
5.9
—
—
—
0
0
14
163
0.83
0.19
1.9
1.7
465.57
469.12
pmol/l
0.02
14
141
9
80
1.14
0.16
3.9
3.6
—
—
—
0
0
9
106
0.83
0.14
1.6
1.6
1.30
1.36
%
—
9
90
13
115
1.15
0.11
2.3
2.1
—
—
—
0
0
17
185
0.90
0.09
7.0
5.9
1.53
1.86
ug/l
0.31
17
169
80
788
1.17
0.07
5.2
6.0
2.81
2.77
mmol/l
0.17
80
734
14
129
1.10
0.06
3.4
3.0
0.87
0.83
mmol/l
1.20
14
124
16
169
0.93
0.03
1.4
1.5
—
—
—
0
0
14
147
0.94
0.01
5.4
4.9
24.68
21.82
%
—
6
71
78
778
1.02
0.00
4.5
5.2
1.50
1.50
mmol/l
0.00
78
721
63
635
0.97
0.00
6.8
4.9
14.67
14.59
pmol/l
0.08
63
597
0
6
0.00
-0.00
0.0
5.2
—
4.44
—
0
6
0
6
0.00
-0.00
0.0
5.2
—
10.73
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
0.57
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
23.22
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_RELAPSPOLYCHONDR and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have M13_RELAPSPOLYCHONDR.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: M13_RELAPSPOLYCHONDR – Relapsing polychondritis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data